Helicos BioSciences has expanded its existing license with Arizona Technology Enterprises, the tech transfer organization for Arizona State University, to include detection methods that do not rely on optically labeled nucleotides, the company said today.

"The newly acquired rights will be an important asset in our licensing and IP monetization efforts," said Ivan Trifunovich, Helicos' president and CEO, in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.

Gene drives might run into biological resistance, the Economist reports.